Effect of delayed microglial specific pparγ activation on ameliorating chronic neuroinflammation and cognitive dysfunction following r-mtbi - brain inflammation is a common feature of repetitive…

The National Institute on Aging awarded The Roskamp Institute, Inc. $468,875 on January 1, 2026, to investigate the effect of delayed microglial-specific PPARG activation on ameliorating chronic neuroinflammation and cognitive dysfunction following repetitive mild traumatic brain injury. The research develops and tests a Cre-LoxP model that overexpresses constitutively active PPARG in microglia, using a preclinical model of repetitive mild TBI to examine whether microglial PPARG signaling specifically mediates the immunomodulatory effects observed with PPARG agonist treatment and whether delayed activation can mitigate cognitive deficits and chronic microglial activation. The award is designated as Trans-NIH Research Support (CFDA 93.310) under the Aging Research program authority. Performance occurs in Sarasota, Florida from January 1, 2026, through December 31, 2027. The Roskamp Institute is a non-profit biotechnology research organization specializing in preclinical neuroscience research, including traumatic brain injury and neurodegenerative disease. This award is one of multiple concurrent National Institute on Aging grants to the institute examining microglial function and brain bioenergetics in the context of aging and TBI.

Effect of delayed microglial specific pparγ activation on ameliorating chronic neuroinflammation and cognitive dysfunction following r-mtbi - brain inflammation is a common feature of repetitive mild TBI mediated neurodegeneration, and this is associated with the maladaptive transformation of microglia from an early neurorestorative phenotype to a persistently dysfunc- tional and chronically activated pro-inflammatory state. Yet, the crucial factors governing the propagation and per- sistence of these diffuse neuroinflammatory responses in the chronic sequelae of TBI remain unknown. To address this, we developed a translationally relevant preclinical model of r-mtbi. Using this model, we generated a molecular library of microglia transcriptomic profiles that provides a detailed time-course of the microglia neuroinflammatory response to TBI. Importantly, we observed deficits in glucose and lipid metabolism, oxidative stress, and a proinflam- matory signature at chronic timepoints, which appeared to be mediated by the loss of constitutive ppar𝛾 signaling. Ppar𝛾 is expressed in multiple cell types and plays a critical role in regulating glucose and lipid metabolism, and inflammation. Treatment with a ppar𝛾 agonist has shown efficacy in mitigating cognitive deficits and chronic MI- croglial activation in our r-mtbi model. However, the use of ppar𝛾 agonists carry several challenges, such as the often reported off-target effects and low BBB penetration. These drugs also lack the specificity needed to target MI- croglial pparγ signaling, and IT remains unknown whether the immunomodulatory effects of pparγ are carried out by microglia, or other CNS cell-types. Further studies are needed to clarify these cell-specific roles to optimize their therapeutic benefits. We recently developed a CRE-loxp model that overexpresses constitutively active pparγ in MI- croglia, and in pilot studies using a pre-injury tamoxifen treatment paradigm, we revealed repression of microglia inflammation and astrogliosis at 30-days post injury (30DPI) and improvement in spatial memory. In this new appli- cation, we will now clarify the constitutive role of pparγ in the chronic stages of TBI and demonstrate whether delayed pparg overexpression in adult microglia (at 90DPI) could serve as a novel target for mitigating chronic neuroinflammation and cognitive deficits. In these studies, we will examine functional and pathological outcomes at 180- and 270-DPI. Finally, we will use a flow cytometry and microglial transcriptomic mining approach to compare TBI-dependent responses in the presence or absence of pparg activation to reveal phenotypic changes in microglia subtypes and neurorestorative mechanisms that correlate with favorable outcomes and represent novel therapeutic targets to block chronic neuroinflammation and the negative consequences of TBI and risk for neurodegenerative diseases. By optimization of the therapeutic effect of boosting pparγ expression in microglia using our novel induc- ible pparg model we aim to maximize pparγ effect and reveal novel tractable targets that result in the same positive downstream consequences of microglial specific pparγ overexpression in the aftermath of TBI that can then be EX- plored as safer and tolerable novel therapies for TBI. Our long-term goal is to identify molecular mechanisms causing posttraumatic neuroinflammation that contribute to progressive brain degeneration and cognitive impairments, in order to develop effective delayed therapeutic interventions to combat neurological complications linked with TBI.